A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting

Allergan

Status: Completed

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Treatments: Drug: Fixed Combination Bimatoprost and Timolol

Study type: Observational

Funder types: Industry

Identifiers

NCT01999348

MAF/AGN/OPH/GLA/039

Details and patient eligibility

About

The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.

Enrollment: 1,553 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with primary open-angle glaucoma or ocular hypertension
• Previously prescribed intraocular pressure (IOP)-lowering medication with insufficient IOP control and is now being switched to GANFORT® UD for medical reasons

Exclusion criteria

• None

Trial design

1,553 participants in 1 patient group

Patients with POAG or OHT

Description:

Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.

Treatment:

Drug: Fixed Combination Bimatoprost and Timolol